---
title: "Exenatide: Parkinson's Drug Pipeline"
description: "A repurposed diabetes drug that raised hopes after a small earlier study, but failed to slow Parkinson's in a larger Phase 3 trial reported in 2024."
canonical_url: "https://parkinsonspathways.com/pipeline/exenatide-pd3"
development_stage: Recently stopped or failed
last_updated: 2026-06-01
source: "Parkinson's Pathways"
---
# Exenatide

**Stage:** Phase 3 failed (2024)  ·  **Type:** Disease-modifying

**Developer:** Academic / investigator-led (a repurposed diabetes drug)

**How it works:** A GLP-1 diabetes drug that was hoped to protect brain cells in Parkinson's.

**Target:** GLP-1 receptor

**Who it's for:** People with Parkinson's (Phase 3 in moderate disease).

**Why it stopped:** The definitive Phase 3 trial (Exenatide-PD3, 2024) found no benefit over placebo, so the Parkinson's program did not proceed.

**Key trials:** NCT04232969

**Last reviewed:** 2026-06-01


## What it is

Exenatide is a GLP-1 diabetes drug. A small 2017 trial generated excitement by suggesting it might slow Parkinson's, making it one of the most-watched repurposing stories in the field.

## Where it stands

The definitive Phase 3 trial (Exenatide-PD3) reported in 2024 that it did not slow Parkinson's. The program for Parkinson's did not move forward on that basis.

## What the data shows so far

Exenatide-PD3 enrolled around 194 people for nearly two years and found no difference between exenatide and placebo on the Parkinson's motor scale: a clear negative result that overrode the earlier, much smaller positive study.

## What families should know

This is an important cautionary tale: a promising small study did not hold up in a larger, rigorous trial. It is why the field insists on confirmatory Phase 3 data before claiming a drug slows Parkinson's. (The related drug lixisenatide had a small positive Phase 2, so the GLP-1 question isn't fully closed, but exenatide itself failed.)

## Caveats

Failed its Phase 3 primary endpoint. The earlier positive Phase 2 was small and did not replicate. Listed here for transparency, not as a treatment to pursue.

## Timeline

_Most recent first._

- **2024**, Phase 3 (Exenatide-PD3) finds no benefit.
- **2017**, Small Phase 2 suggests a possible benefit.

## Sources

- [Exenatide-PD3 on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04232969)

_Last reviewed: 2026-06-01._

## More

- [Back to the Parkinson's drug pipeline](https://parkinsonspathways.com/pipeline)
- [Browse all recruiting trials](https://parkinsonspathways.com/trials)